LE WE PMID CA
Schizophrenia8Schizophrenie

Addiction (Drugs of abuse)

Antipsychotic agents

Aripiprazole

Asenapine

Bipolar disorder

Cannabis

Cholinesterase inhibitor

CNTNAP2

Cognitive behavior therapy

Endocrine disruptor

Endophenotype

Hallucination

Hippocampus

Homicide

Host pathogen interaction

Influenza

Kynurenic acid

Learning and memory (Neurophysiology)

Negative symptom

Nicotine

Nogo

NRXN1 Neurexin1

Orexin

Paliperidone

Physician patient relationship

Pitt Hopkins syndrome

Prepulse inhibition (Neurophysiology)

Psychosis

Psychosurgery

Receptor (Glutamate metabotropic)

Risperidone

Schizoaffective personality disorder

Schizophrenia

Schizotypic personality disorder

Subiculum

Sulpiride

TCF4

Vitamin B3

Ziprasidone

2009  
1
What we know: findings that every theory of schizophrenia should explain.
[19329559] Schizophr Bull 35(3): 493-508 (2009)
2009  
2
The dopamine hypothesis of schizophrenia: version III--the final common pathway.
[19325164] Schizophr Bull 35(3): 549-62 (2009)
2009  
3
The neurodevelopmental hypothesis of schizophrenia, revisited.
[19223657] Schizophr Bull 35(3): 528-48 (2009)
2009  
4
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring.
[19155345] Schizophr Bull 35(3): 509-27 (2009)
2009  
5
The antecedents of schizophrenia: a review of birth cohort studies.
[18658128] Schizophr Bull 35(3): 603-23 (2009)
2009  
6
Psychosocial treatments to promote functional recovery in schizophrenia.
[19176470] Schizophr Bull 35(2): 347-61 (2009)
2009  
7
Psychiatric comorbidities and schizophrenia.
[19011234] Schizophr Bull 35(2): 383-402 (2009)
2009  
8
Physical manifestations of neurodevelopmental disruption: are minor physical anomalies part of the syndrome of schizophrenia?
[18990714] Schizophr Bull 35(2): 425-36 (2009)
2009  
9
Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.
[18791074] Schizophr Bull 35(2): 415-24 (2009)
2009  
10
Does the addition of a second antipsychotic drug improve clozapine treatment?
[18436527] Schizophr Bull 35(2): 458-68 (2009)
2009  
11
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
[18417466] Schizophr Bull 35(2): 443-57 (2009)
2009  
12
Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium.
[19023124] Schizophr Bull 35(1): 15-8 (2009)
2009  
13
Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.
[18245062] Schizophr Bull 35(1): 256-78 (2009)
2008  
14
Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions.
[18791076] Schizophr Bull 34(6): 1066-82 (2008)
2008  
15
The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.
[18263882] Schizophr Bull 34(2): 312-21 (2008)
2008  
16
Limbic structures and networks in children and adolescents with schizophrenia.
[17942479] Schizophr Bull 34(1): 18-29 (2008)
2008  
17
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.
[17923452] Schizophr Bull 34(1): 60-71 (2008)
2008  
18
Cortical brain development in schizophrenia: insights from neuroimaging studies in childhood-onset schizophrenia.
[17906336] Schizophr Bull 34(1): 30-6 (2008)
2008  
19
A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia.
[17573357] Schizophr Bull 34(1): 181-92 (2008)
2008  
20
The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences.
[17562694] Schizophr Bull 34(1): 155-72 (2008)
2007  
21
Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review.
[17289653] Schizophr Bull 33(6): 1324-42 (2007)
2007  
22
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
[17641146] Schizophr Bull 33(5): 1120-30 (2007)
2007  
23
Molecular targets for treating cognitive dysfunction in schizophrenia.
[17617664] Schizophr Bull 33(5): 1100-19 (2007)
2007  
24
Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?
[17519393] Schizophr Bull 33(4): 971-81 (2007)
2007  
25
Are anticorrelated networks in the brain relevant to schizophrenia?
[17493957] Schizophr Bull 33(4): 994-1003 (2007)
2007  
26
Application of electroencephalography to the study of cognitive and brain functions in schizophrenia.
[17363840] Schizophr Bull 33(4): 955-70 (2007)
2007  
27
Persistent negative symptoms in schizophrenia: an overview.
[17099070] Schizophr Bull 33(4): 1013-22 (2007)
2007  
28
Psychomotor slowing in schizophrenia.
[17093141] Schizophr Bull 33(4): 1038-53 (2007)
2007  
29
Schizophrenia and monothematic delusions.
[17372282] Schizophr Bull 33(3): 642-7 (2007)
2007  
30
Perceptual anomalies in schizophrenia: integrating phenomenology and cognitive neuroscience.
[17118973] Schizophr Bull 33(1): 142-56 (2007)
2007  
31
Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma--a critical review.
[17105965] Schizophr Bull 33(1): 3-10 (2007)
2006  
32
Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.
[16905634] Schizophr Bull 32 Suppl 1(-): S64-80 (2006)
2006  
33
Neurobiological correlates of violent behavior among persons with schizophrenia.
[16384876] Schizophr Bull 32(3): 562-72 (2006)
2006  
34
Subdomains within the negative symptoms of schizophrenia: commentary.
[16492798] Schizophr Bull 32(2): 246-9 (2006)
2006  
35
Treatment of schizophrenia negative symptoms: future prospects.
[16492797] Schizophr Bull 32(2): 234-7 (2006)
2006  
36
The NIMH-MATRICS consensus statement on negative symptoms.
[16481659] Schizophr Bull 32(2): 214-9 (2006)
2006  
37
The structure of negative symptoms within schizophrenia: implications for assessment.
[16254064] Schizophr Bull 32(2): 238-45 (2006)
2006  
38
Anhedonia in schizophrenia: a review of assessment strategies.
[16221997] Schizophr Bull 32(2): 259-73 (2006)
2006  
39
Negative symptoms and cognitive deficits: what is the nature of their relationship?
[16221995] Schizophr Bull 32(2): 250-8 (2006)
2006  
40
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.
[16207892] Schizophr Bull 32(1): 166-78 (2006)
2005  
41
Significance and meaning of neurological signs in schizophrenia: two decades later.
[15958818] Schizophr Bull 31(4): 962-77 (2005)
2005  
42
Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia.
[16020551] Schizophr Bull 31(3): 672-96 (2005)
2005  
43
Cortical cholinergic transmission and cortical information processing in schizophrenia.
[15888431] Schizophr Bull 31(1): 117-38 (2005)
2005  
44
"Theory of mind" in schizophrenia: a review of the literature.
[15888423] Schizophr Bull 31(1): 21-42 (2005)
2004  
45
Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms.
[15954196] Schizophr Bull 30(4): 875-900 (2004)
2004  
46
Sexuality and schizophrenia: a review.
[15954189] Schizophr Bull 30(4): 767-79 (2004)
2004  
47
What is the functional significance of hippocampal pathology in schizophrenia?
[15279054] Schizophr Bull 30(2): 367-92 (2004)
2003  
48
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus.
[14989416] Schizophr Bull 29(4): 803-30 (2003)
2003  
49
Transition to schizophrenia and related disorders: toward a taxonomy of risk.
[14989407] Schizophr Bull 29(4): 693-701 (2003)
2003  
50
Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions.
[14989405] Schizophr Bull 29(4): 653-69 (2003)
2003  
51
Schizophrenia, consciousness, and the self.
[14609238] Schizophr Bull 29(3): 427-44 (2003)
2003  
52
A review of cognitive training in schizophrenia.
[14552510] Schizophr Bull 29(2): 359-82 (2003)
2002  
53
The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome.
[12047023] Schizophr Bull 28(1): 63-73 (2002)
2002  
54
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
[12047022] Schizophr Bull 28(1): 5-16 (2002)
2001  
55
Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities.
[11596845] Schizophr Bull 27(3): 431-42 (2001)
2001  
56
Genetic insights into the neurodevelopmental hypothesis of schizophrenia.
[11596844] Schizophr Bull 27(3): 417-30 (2001)
2001  
57
Challenges, status, and opportunities for studying developmental neuropathology in adult schizophrenia.
[11596843] Schizophr Bull 27(3): 395-416 (2001)
2001  
58
Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease.
[11596841] Schizophr Bull 27(3): 349-77 (2001)
2001  
59
Shaping attention span: an operant conditioning procedure to improve neurocognition and functioning in schizophrenia.
[11354592] Schizophr Bull 27(2): 247-57 (2001)
2000  
60
The deficit syndrome and eye tracking disorder may reflect a distinct subtype within the syndrome of schizophrenia.
[11087018] Schizophr Bull 26(4): 855-66 (2000)
2000  
61
Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes.
[10993392] Schizophr Bull 26(3): 517-25 (2000)
1999  
62
Practice principles of cognitive enhancement therapy for schizophrenia.
[10667740] Schizophr Bull 25(4): 693-708 (1999)
1999  
63
Developmental theory for a cognitive enhancement therapy of schizophrenia.
[10667739] Schizophr Bull 25(4): 677-92 (1999)
1999  
64
Schizophrenia: an epigenetic puzzle?
[10667737] Schizophr Bull 25(4): 639-55 (1999)
1999  
65
At issue: schizophrenia and rheumatoid arthritis: the negative association revisited.
[10667736] Schizophr Bull 25(4): 625-38 (1999)
1999  
66
Schizophrenia and complications of pregnancy and labor: an individual patient data meta-analysis.
[10478777] Schizophr Bull 25(3): 413-23 (1999)
1999  
67
Outcome of schizophrenia in relation to brain abnormalities.
[10416735] Schizophr Bull 25(2): 337-48 (1999)
1999  
68
Should schizophrenia be treated as a neurocognitive disorder?
[10416733] Schizophr Bull 25(2): 309-19 (1999)
1999  
69
Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation.
[10416731] Schizophr Bull 25(2): 275-89 (1999)
1999  
70
Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies.
[10416730] Schizophr Bull 25(2): 257-74 (1999)
1999  
71
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
[10416729] Schizophr Bull 25(2): 233-55 (1999)
1999  
72
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
[10416727] Schizophr Bull 25(2): 201-22 (1999)
1999  
73
Interventions for neurocognitive deficits: editor's introduction.
[10416726] Schizophr Bull 25(2): 197-200 (1999)
1999  
74
Laterality in functional brain imaging studies of schizophrenia.
[10098918] Schizophr Bull 25(1): 141-56 (1999)
1999  
75
Structural asymmetries of the human brain and their disturbance in schizophrenia.
[10098917] Schizophr Bull 25(1): 121-39 (1999)
1999  
76
Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation.
[10098916] Schizophr Bull 25(1): 91-120 (1999)
1999  
77
Atypical handedness in schizophrenia: some methodological and theoretical issues.
[10098914] Schizophr Bull 25(1): 63-78 (1999)
1999  
78
Laterality in animals: relevance to schizophrenia.
[10098913] Schizophr Bull 25(1): 41-62 (1999)
1999  
79
Is Schizophrenia a lateralized brain disorder? Editor's introduction.
[10098911] Schizophr Bull 25(1): 7-9 (1999)
1998  
80
The Russian concept of schizophrenia: a review of the literature.
[9853788] Schizophr Bull 24(4): 537-57 (1998)
1998  
81
Facial expressions of emotions and schizophrenia: a review.
[9718632] Schizophr Bull 24(3): 399-412 (1998)
1998  
82
Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia.
[9613626] Schizophr Bull 24(2): 285-301 (1998)
1998  
83
Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters.
[9613625] Schizophr Bull 24(2): 267-83 (1998)
1998  
84
1998  
85
Limbic-cortical neuronal damage and the pathophysiology of schizophrenia.
[9613623] Schizophr Bull 24(2): 231-48 (1998)
1998  
86
Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain.
[9613622] Schizophr Bull 24(2): 219-30 (1998)
1998  
87
"Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?
[9613621] Schizophr Bull 24(2): 203-18 (1998)
1998  
88
Schizophrenia, sensory gating, and nicotinic receptors.
[9613620] Schizophr Bull 24(2): 189-202 (1998)
1998  
89
A review of neuropsychological differences between paranoid and nonparanoid schizophrenia patients.
[9502551] Schizophr Bull 24(1): 127-45 (1998)
1997  
90
Evaluation of treatment-resistant schizophrenia.
[9366002] Schizophr Bull 23(4): 663-74 (1997)
1997  
91
The temporolimbic system theory of paranoid schizophrenia.
[9327514] Schizophr Bull 23(3): 513-5 (1997)
1997  
92
Neuroanatomy of schizophrenia.
[9327513] Schizophr Bull 23(3): 509-12 (1997)
1997  
93
Cortical development and thalamic pathology in schizophrenia.
[9327511] Schizophr Bull 23(3): 483-501 (1997)
1997  
94
Functional and anatomical aspects of prefrontal pathology in schizophrenia.
[9327508] Schizophr Bull 23(3): 437-58 (1997)
1997  
95
The temporolimbic system theory of positive schizophrenic symptoms.
[9327507] Schizophr Bull 23(3): 423-35 (1997)
1997  
96
Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems.
[9327506] Schizophr Bull 23(3): 403-21 (1997)
1997  
97
Postmortem studies of the hippocampal formation in schizophrenia.
[9327505] Schizophr Bull 23(3): 385-402 (1997)
1997  
98
Anatomy of schizophrenia revisited.
[9327504] Schizophr Bull 23(3): 373-83 (1997)
1997  
99
The neuroanatomies of schizophrenia.
[9327503] Schizophr Bull 23(3): 367-72 (1997)
1997  
100
Perseveration in schizophrenia.
[9050113] Schizophr Bull 23(1): 63-74 (1997)
1997  
101
A cognitive neuroscience view of schizophrenic thought disorder.
[9050111] Schizophr Bull 23(1): 29-50 (1997)
1996  
102
Neuroimaging and the cognitive neuroscience of schizophrenia.
[8938923] Schizophr Bull 22(4): 703-25 (1996)
1996  
103
First-episode schizophrenia: I. Early course parameters.
[8782284] Schizophr Bull 22(2): 241-56 (1996)
1996  
104
Early detection and intervention with schizophrenia: rationale.
[8782282] Schizophr Bull 22(2): 201-22 (1996)
1995  
105
Conventional antipsychotic medications for schizophrenia.
[8749885] Schizophr Bull 21(4): 567-77 (1995)
1995  
106
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia.
[8749883] Schizophr Bull 21(4): 553-9 (1995)
1995  
107
Prodromal symptoms and relapse prevention in schizophrenia.
[8749882] Schizophr Bull 21(4): 541-51 (1995)
1995  
108
Prodromal symptoms of relapse in schizophrenia: a review.
[8749881] Schizophr Bull 21(4): 527-39 (1995)
1995  
109
The multidimensionality of schizotypy.
[7770738] Schizophr Bull 21(1): 19-31 (1995)
1995  
110
Cerebellum and schizophrenia: a selective review.
[7631171] Schizophr Bull 21(2): 241-50 (1995)
1994  
111
Eye tracking and schizophrenia: a selective review.
[8197421] Schizophr Bull 20(1): 47-62 (1994)
1994  
112
Impaired attention, genetics, and the pathophysiology of schizophrenia.
[8197420] Schizophr Bull 20(1): 31-46 (1994)
1994  
113
Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: an update.
[8197410] Schizophr Bull 20(1): 121-35 (1994)
1994  
114
Neuropsychological risk indicators for schizophrenia: a review of family studies.
[8197409] Schizophr Bull 20(1): 103-19 (1994)
1994  
115
Pain insensitivity in schizophrenia: a neglected phenomenon and some implications.
[8085127] Schizophr Bull 20(2): 235-48 (1994)
1994  
116
Classifying the courses of schizophrenia.
[7973468] Schizophr Bull 20(3): 519-36 (1994)
1994  
117
Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy.
[7701278] Schizophr Bull 20(4): 713-25 (1994)
1994  
118
The clinical presentation of childhood-onset schizophrenia.
[7701273] Schizophr Bull 20(4): 631-46 (1994)
1994  
119
Developmentally moderated expressions of the neuropathology underlying schizophrenia.
[7526447] Schizophr Bull 20(3): 453-80 (1994)
1993  
120
Neurodynamics of abnormalities in cerebral metabolism and structure in schizophrenia.
[8451613] Schizophr Bull 19(1): 55-69 (1993)
1993  
121
Parallel distributed processing and the emergence of schizophrenic symptoms.
[8451607] Schizophr Bull 19(1): 119-40 (1993)
1993  
122
Recent advances in the neuropathology of schizophrenia.
[8322039] Schizophr Bull 19(2): 431-45 (1993)
1993  
123
Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal.
[8322038] Schizophr Bull 19(2): 355-70 (1993)
1993  
124
Neuroimaging in schizophrenia research.
[8322037] Schizophr Bull 19(2): 337-53 (1993)
1993  
125
Psychosocial treatment for schizophrenia.
[8322036] Schizophr Bull 19(2): 317-36 (1993)
1993  
126
Information processing and attention dysfunctions in schizophrenia.
[8322034] Schizophr Bull 19(2): 233-59 (1993)
1993  
127
Relations of symptoms to cognitive deficits in schizophrenia.
[8322033] Schizophr Bull 19(2): 215-31 (1993)
1993  
128
Diagnosis and classification of schizophrenia.
[8322032] Schizophr Bull 19(2): 199-214 (1993)
1993  
129
Alzheimer-type neuropathology in elderly schizophrenia patients.
[8303229] Schizophr Bull 19(4): 805-16 (1993)
1993  
130
Course of schizophrenia: neuropsychological evidence for a static encephalopathy.
[8303228] Schizophr Bull 19(4): 797-804 (1993)
1993  
131
Neurobiological investigations in cingulate cortex of schizophrenic brain.
[8235456] Schizophr Bull 19(3): 537-49 (1993)
1993  
132
Eye tracking dysfunction and schizophrenia: a critical perspective.
[8235455] Schizophr Bull 19(3): 461-536 (1993)
1993  
133
Neurochemistry and neuroendocrinology of schizophrenia: a selective review.
[8100644] Schizophr Bull 19(2): 371-429 (1993)
1993  
134
Psychopharmacologic treatment of schizophrenia.
[8100642] Schizophr Bull 19(2): 287-302 (1993)
1993  
135
Low-dose depot medication in schizophrenia.
[8095736] Schizophr Bull 19(1): 155-64 (1993)
1993  
136
Treatment of late-life schizophrenia with neuroleptics.
[7905663] Schizophr Bull 19(4): 817-30 (1993)
1992  
137
The natural course of schizophrenia: a review of first-admission studies.
[1621068] Schizophr Bull 18(2): 185-207 (1992)
1992  
138
Relapse of paranoid psychotic state in methamphetamine model of schizophrenia.
[1553491] Schizophr Bull 18(1): 115-22 (1992)
1992  
139
A neurodevelopmental approach to the classification of schizophrenia.
[1377834] Schizophr Bull 18(2): 319-32 (1992)
1992  
140
The significance of age of onset for schizophrenia.
[1377833] Schizophr Bull 18(2): 209-15 (1992)
1992  
141
Treatment of the neuroleptic-nonresponsive schizophrenic patient.
[1357741] Schizophr Bull 18(3): 515-42 (1992)
1991  
142
The diagnosis of schizophrenia: a review of onset and duration issues.
[2047789] Schizophr Bull 17(1): 51-67 (1991)
1991  
143
Counterpoint: a sensory gating--hippocampal model of schizophrenia.
[2047787] Schizophr Bull 17(1): 19-24 (1991)
1991  
144
A viral-anatomical explantation of schizophrenia.
[2047784] Schizophr Bull 17(1): 15-8 (1991)
1991  
145
Classical subtypes for schizophrenia: literature review for DSM-IV.
[1822677] Schizophr Bull 17(4): 609-32 (1991)
1991  
146
Neuroleptics and the natural course of schizophrenia.
[1679255] Schizophr Bull 17(2): 325-51 (1991)
1991  
147
Maintenance medication for schizophrenia: strategies for dose reduction.
[1679254] Schizophr Bull 17(2): 311-24 (1991)
1991  
148
When symptoms persist: choosing among alternative somatic treatments for schizophrenia.
[1679252] Schizophr Bull 17(2): 217-45 (1991)
1990  
149
Temporal lobe asymmetries as the key to the etiology of schizophrenia.
[2287933] Schizophr Bull 16(3): 433-43 (1990)
1990  
150
The case of frontostriatal dysfunction in schizophrenia.
[2287930] Schizophr Bull 16(3): 391-402 (1990)
1990  
151
The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia.
[2287929] Schizophr Bull 16(3): 379-89 (1990)
1990  
152
Significance of the positive-negative distinction in schizophrenia.
[2077641] Schizophr Bull 16(4): 635-52 (1990)
1990  
153
Evidence for reduced and dysregulated turnover of dopamine in schizophrenia.
[2077638] Schizophr Bull 16(4): 605-15 (1990)
1990  
154
Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients.
[1981108] Schizophr Bull 16(3): 477-99 (1990)
1990  
155
Schizophrenia: a subcortical neurotransmitter imbalance syndrome?
[1981107] Schizophr Bull 16(3): 425-32 (1990)
1989  
156
Schizophrenia and the self: contributions of psychoanalytic self-psychology.
[2665054] Schizophr Bull 15(2): 311-22 (1989)
1988  
157
Late-onset schizophrenia: an overview.
[3291094] Schizophr Bull 14(1): 39-55 (1988)
1988  
158
The neuropathology of schizophrenia.
[3059468] Schizophr Bull 14(2): 209-16 (1988)
1988  
159
Probing prefrontal function in schizophrenia with neuropsychological paradigms.
[3059467] Schizophr Bull 14(2): 179-83 (1988)
1987  
160
The positive and negative syndrome scale (PANSS) for schizophrenia.
[3616518] Schizophr Bull 13(2): 261-76 (1987)
1987  
161
Studies toward the subcortical pathogenesis of schizophrenia.
[3326160] Schizophr Bull 13(4): 555-76 (1987)
1983  
162
Neuropathological studies of schizophrenia: a selective review.
[6346480] Schizophr Bull 9(2): 193-212 (1983)
1982  
163
Social dysfunction and treatment failure in schizophrenia.
[7071538] Schizophr Bull 8(1): 85-98 (1982)
1981  
164
Diagnosis of schizophrenia: a critical review of current diagnostic systems.
[7280573] Schizophr Bull 7(3): 452-76 (1981)
1980  
165
Biochemical processes in schizophrenia: an update.
[6996079] Schizophr Bull 6(3): 393-403 (1980)
1979  
166
Recent studies of psychophysiology in schizophrenia.
[42141] Schizophr Bull 5(4): 581-611 (1979)
1979  
167
Biology of schizophrenia subtypes: a review and proposal for method of study.
[39334] Schizophr Bull 5(3): 460-79 (1979)
1978  
168
Animal models of schizophrenia: the case for LSD-25.
[746371] Schizophr Bull 4(2): 186-209 (1978)
1977  
169
Qualitative and quantitative EEG findings in schizophrenia.
[325642] Schizophr Bull 3(1): 61-79 (1977)
1976  
170
The dopamine hypothesis of schizophrenia: a review.
[779020] Schizophr Bull 2(1): 19-76 (1976)
1976  
171
Neuromuscular dysfunction in schizophrenia.
[779019] Schizophr Bull 2(1): 106-35 (1976)
2003  
172
Integrated treatment of schizophrenia.
[14600309] Psychiatr Serv 54(11): 1499-507 (2003)
1970  
173
Drive theories of schizophrenia.
[4908902] Psychosom Med 32(2): 113-40 (1970)
1967  
174
Variations in cognitive control and psychophysiological defense in the schizophrenias.
[5340350] Psychosom Med 29(3): 225-51 (1967)
1996  
175
Advances in psychopharmacology--schizophrenia.
[8949257] Br Med Bull 52(3): 556-74 (1996)
2006  
176
Aripiprazole for schizophrenia. Systematic review.
[16880478] Br J Psychiatry 189(-): 102-8 (2006)
2005  
177
Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes.
[16135855] Br J Psychiatry 187(-): 203-5 (2005)
2005  
178
Schizophrenia practice guidelines: international survey and comparison.
[16135862] Br J Psychiatry 187(-): 248-55 (2005)
2008  
179
Divergent approaches converge on frontal lobe dysfunction in schizophrenia.
[18676596] Am J Psychiatry 165(8): 944-8 (2008)
2006  
180
2004  
181
The pathophysiology of schizophrenia disorders: perspectives from the spectrum.
[14992962] Am J Psychiatry 161(3): 398-413 (2004)
2002  
182
Atypical antipsychotic medications and the treatment of schizophrenia.
[11823256] Am J Psychiatry 159(2): 177-9 (2002)
2001  
183
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
[11532718] Am J Psychiatry 158(9): 1367-77 (2001)
2001  
184
Changing concepts in the neurochemistry of schizophrenia.
[11532717] Am J Psychiatry 158(9): 1365-6 (2001)
2001  
185
The psychosocial treatment of schizophrenia: an update.
[11156795] Am J Psychiatry 158(2): 163-75 (2001)
1999  
186
Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
[10450252] Am J Psychiatry 156(8): 1138-48 (1999)
1999  
187
Searching for the neuropathology of schizophrenia: neuroimaging strategies and findings.
[10450250] Am J Psychiatry 156(8): 1133-6 (1999)
1999  
188
Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.
[10401441] Am J Psychiatry 156(7): 990-9 (1999)
1999  
189
Long-term care of an individual with schizophrenia: pharmacologic, psychological, and social factors.
[9892307] Am J Psychiatry 156(1): 124-8 (1999)
2005  
190
Long-term outcome of patients with schizophrenia: a review.
[16494258] Can J Psychiatry 50(14): 892-900 (2005)
2005  
191
Clinical practice guidelines. Treatment of schizophrenia.
[16529334] Can J Psychiatry 50(13 Suppl 1): 7S-57S (2005)
2005  
192
The negative symptoms of schizophrenia: a cognitive perspective.
[15968839] Can J Psychiatry 50(5): 247-57 (2005)
1998  
193
Canadian clinical practice guidelines for the treatment of schizophrenia. The Canadian Psychiatric Association.
[9825175] Can J Psychiatry 43 Suppl 2(-): 25S-40S (1998)
2009  
194
Schizophrenia pathophysiology: are we any closer to a complete model?
[19445674] Ann Gen Psychiatry 8(-): 12 (2009)
2007  
195
Suicide risk in schizophrenia: learning from the past to change the future.
[17367524] Ann Gen Psychiatry 6(-): 10 (2007)
2009  
196
Organization of cognitive control within the lateral prefrontal cortex in schizophrenia.
[19349307] Arch Gen Psychiatry 66(4): 377-86 (2009)
2005  
197
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
[15753239] Arch Gen Psychiatry 62(3): 263-72 (2005)
2003  
198
Guideline recommendations for treatment of schizophrenia: the impact of managed care.
[12695310] Arch Gen Psychiatry 60(4): 340-8 (2003)
2009  
199
Fronto-temporal dysfunction in schizophrenia: A selective review.
[19881045] Indian J Psychiatry 51(3): 180-90 (2009)
2003  
200
Pathogenesis of schizophrenia: Part I. Symptomatology, cognitive characteristics and brain morphology.
[12519448] Psychiatry Clin Neurosci 57(1): 3-8 (2003)
2003  
201
Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis.
[12519449] Psychiatry Clin Neurosci 57(1): 9-15 (2003)
2010  
202
The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.
[19786963] Mol Psychiatry 15(2): 122-37 (2010)
2008  
203
Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia.
[18728804] Neuropsychiatr Dis Treat 4(1): 55-68 (2008)
2007  
204
Patterns of anterior cingulate activation in schizophrenia: a selective review.
[19300540] Neuropsychiatr Dis Treat 3(1): 87-101 (2007)
2006  
205
A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder.
[19412492] Neuropsychiatr Dis Treat 2(4): 427-43 (2006)
2010  
206
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.
[20223196] Neuron 65(5): 585-96 (2010)
2006  
207
Neurobiology of schizophrenia.
[17015232] Neuron 52(1): 139-53 (2006)
2003  
208
The synaptic hypothesis of schizophrenia.
[12873379] Neuron 39(2): 205-16 (2003)
2000  
209
Catching up on schizophrenia: natural history and neurobiology.
[11144342] Neuron 28(2): 325-34 (2000)
2003  
210
Cortical coordination dynamics and the disorganization syndrome in schizophrenia.
[12827142] Neuropsychopharmacology 28 Suppl 1(-): S35-9 (2003)
2002  
211
Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation.
[12377404] Neuropsychopharmacology 27(4): 672-83 (2002)
2001  
212
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.
[11377916] Neuropsychopharmacology 25(1): 1-27 (2001)
2000  
213
Assessing the efficacy of treatments for the deficit syndrome of schizophrenia.
[10693158] Neuropsychopharmacology 22(3): 303-10 (2000)
1995  
214
New insights into the biology of schizophrenia through the mechanism of action of clozapine.
[8602893] Neuropsychopharmacology 13(3): 177-213 (1995)
1995  
215
Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia.
[7766284] Neuropsychopharmacology 12(1): 3-16 (1995)
2010  
216
Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.
[20089137] J Neurochem 113(2): 287-302 (2010)
2009  
217
Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
[19686383] J Neurochem 111(4): 891-900 (2009)
2008  
218
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
[18957051] J Neurochem 107(5): 1188-95 (2008)
2002  
219
Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine.
[12472879] J Neurochem 83(6): 1241-51 (2002)
2010  
220
The assessment of neuropsychological functioning in schizophrenia.
[20954432] Dialogues Clin Neurosci 12(3): 383-92 (2010)
2010  
221
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.
[20954431] Dialogues Clin Neurosci 12(3): 359-82 (2010)
2010  
222
Pharmacologic treatment of schizophrenia.
[20954430] Dialogues Clin Neurosci 12(3): 345-57 (2010)
2010  
223
Functional magnetic resonance imaging in schizophrenia.
[20954429] Dialogues Clin Neurosci 12(3): 333-43 (2010)
2010  
224
Structural neuroimaging in schizophrenia: from methods to insights to treatments.
[20954428] Dialogues Clin Neurosci 12(3): 317-32 (2010)
2010  
225
Genetics in schizophrenia: where are we and what next?
[20954426] Dialogues Clin Neurosci 12(3): 289-303 (2010)
2009  
226
Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia.
[19877495] Dialogues Clin Neurosci 11(3): 269-80 (2009)
2006  
227
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery.
[16640125] Dialogues Clin Neurosci 8(1): 137-42 (2006)
2006  
228
Understanding structural brain changes in schizophrenia.
[16640116] Dialogues Clin Neurosci 8(1): 71-8 (2006)
2006  
229
A review of emotion deficits in schizophrenia.
[16640115] Dialogues Clin Neurosci 8(1): 59-70 (2006)
2005  
230
Intermediate phenotypes in schizophrenia: a selective review.
[16262211] Dialogues Clin Neurosci 7(2): 165-79 (2005)
2005  
231
The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia.
[16262208] Dialogues Clin Neurosci 7(2): 125-35 (2005)
2007  
232
Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
[17627670] CNS Drug Rev 13(2): 137-77 (2007)
2008  
233
Muscarinic agonists for the treatment of cognition in schizophrenia.
[19037177] CNS Spectr 13(11): 985-96 (2008)
2009  
234
Left temporal lobe structural and functional abnormality underlying auditory hallucinations in schizophrenia.
[19753095] Front Neurosci 3(1): 34-45 (2009)
1999  
235
The use of atypical antipsychotics in the management of schizophrenia.
[10073734] Br J Clin Pharmacol 47(1): 13-22 (1999)
2003  
236
A systematic review of atypical antipsychotic drugs in schizophrenia.
[12925268] Health Technol Assess 7(13): 1-193 (2003)
2002  
237
The psychopathology, medical management and dental implications of schizophrenia.
[12036166] J Am Dent Assoc 133(5): 603-10; quiz 624-5 (2002)
1999  
238
The neuropathology of schizophrenia. A critical review of the data and their interpretation.
[10219775] Brain 122 ( Pt 4)(-): 593-624 (1999)
1961  
239
The etiology of schizophrenia. A review.
[13699087] Calif Med 94(-): 369-77 (1961)
2009  
240
Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies.
[19339762] J Clin Invest 119(4): 706-16 (2009)
2006  
241
Schizophrenia: an integrative approach to modelling a complex disorder.
[16699601] J Psychiatry Neurosci 31(3): 157-67 (2006)
2005  
242
Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia?
[15944743] J Psychiatry Neurosci 30(3): 187-93 (2005)
2001  
243
Animal models of schizophrenia: a critical review.
[11762207] J Psychiatry Neurosci 26(5): 395-410 (2001)
2000  
244
Treating cognitive dysfunction in patients with schizophrenia.
[10740985] J Psychiatry Neurosci 25(2): 117-24 (2000)
1991  
245
Structural and functional brain imaging in schizophrenia.
[1911736] J Psychiatry Neurosci 16(2): 53-74 (1991)
2002  
246
Genetics and etiopathophysiology of schizophrenia.
[12374251] Mayo Clin Proc 77(10): 1068-82 (2002)
2002  
247
Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.
[11884695] Postgrad Med J 78(917): 142-8 (2002)
1987  
248
2010  
249
The hippocampal formation in schizophrenia.
[20810471] Am J Psychiatry 167(10): 1178-93 (2010)
2006  
250
Cognitive behavior therapy for schizophrenia.
[16513854] Am J Psychiatry 163(3): 365-73 (2006)
2003  
251
The neural substrates of affect impairment in schizophrenia.
[14514479] Am J Psychiatry 160(10): 1723-5 (2003)
2010  
252
Investigating the cognitive antecedents of schizophrenia.
[20123918] Am J Psychiatry 167(2): 122-4 (2010)
2010  
253
The use of depot medications in the treatment of schizophrenia.
[20123919] Am J Psychiatry 167(2): 125-6 (2010)
2008  
254
Pharmacological treatment of cognition in schizophrenia: an idea whose method has come.
[18245181] Am J Psychiatry 165(2): 163-5 (2008)
2008  
255
The risk for schizophrenia from childhood and adult infections.
[18178749] Am J Psychiatry 165(1): 7-10 (2008)
2008  
256
Successful treatment of schizophrenia requires optimal daily doses of vitamin B3.
[19238764] Altern Med Rev 13(4): 287-91 (2008)
2009  
257
Epigenetic mechanisms in schizophrenia.
[19559755] Biochim Biophys Acta 1790(9): 869-77 (2009)
2007  
258
Chronic auditory hallucinations in schizophrenic patients: MR analysis of the coincidence between functional and morphologic abnormalities.
[17641373] Radiology 244(2): 549-56 (2007)
2011  
259
Challenges of analysing gene-environment interactions in mouse models of schizophrenia.
[21789475] ScientificWorldJournal 11(-): 1411-20 (2011)
2009  
260
Schizophrenia (maintenance treatment).
[19445748] Clin Evid (Online) 2009(-): - (2009)
2009  
261
Converging evidence for the Nogo-66 receptor gene in schizophrenia.
[19386899] J Neurosci 29(16): 5045-7 (2009)
2009  
262
Potential endophenotype for schizophrenia: neurological soft signs.
[19521640] Ann Acad Med Singapore 38(5): 408-6 (2009)
2003  
263
Recent advances in the neurobiology of schizophrenia.
[14993436] Mol Interv 3(1): 27-39 (2003)
2010  
264
Aripiprazole for late-life schizophrenia.
[20852672] Clin Interv Aging 5(-): 253-8 (2010)
2009  
265
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.
[19269307] Pharmacol Ther 122(2): 150-202 (2009)
2011  
266
Paliperidone extended-release: does it have a place in antipsychotic therapy?
[21448450] Drug Des Devel Ther 5(-): 125-46 (2011)
2010  
267
TCF4, schizophrenia, and Pitt-Hopkins Syndrome.
[20421335] Schizophr Bull 36(3): 443-7 (2010)
2010  
268
Dopaminergic dysfunction in schizophrenia: salience attribution revisited.
[20453041] Schizophr Bull 36(3): 472-85 (2010)
2008  
269
Affective traits in schizophrenia and schizotypy.
[18667393] Schizophr Bull 34(5): 856-74 (2008)
2010  
270
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.
[19955388] Schizophr Bull 36(1): 94-103 (2010)
2010  
271
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.
[19955389] Schizophr Bull 36(1): 48-70 (2010)
2010  
272
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
[19955390] Schizophr Bull 36(1): 71-93 (2010)
2010  
273
Schizophrenia and 1957 pandemic of influenza: meta-analysis.
[19959706] Schizophr Bull 36(2): 219-28 (2010)
2010  
274
Rates of homicide during the first episode of psychosis and after treatment: a systematic review and meta-analysis.
[18990713] Schizophr Bull 36(4): 702-12 (2010)
2010  
275
Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia.
[20154202] Schizophr Bull 36(2): 243-5 (2010)
2010  
276
Sulpiride augmentation for schizophrenia.
[20061345] Schizophr Bull 36(2): 229-30 (2010)
2010  
277
Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.
[20147364] Schizophr Bull 36(2): 211-8 (2010)
2010  
278
Cognitive impairment in affective psychoses: a meta-analysis.
[19767349] Schizophr Bull 36(1): 112-25 (2010)
2010  
279
Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.
[19776206] Schizophr Bull 36(1): 36-42 (2010)
2007  
280
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date.
[17159230] Schizophr Bull 33(5): 1201-12 (2007)
2007  
281
The orexins/hypocretins and schizophrenia.
[17728265] Schizophr Bull 33(6): 1277-83 (2007)
2008  
282
Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"?
[18408230] Schizophr Bull 34(4): 774-90 (2008)
2008  
283
The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia.
[18562344] Schizophr Bull 34(5): 927-43 (2008)
2008  
284
Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia.
[18544550] Schizophr Bull 34(5): 962-73 (2008)
2010  
285
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.
[19934211] Schizophr Bull 36(2): 271-88 (2010)
2010  
286
Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models.
[19903746] Schizophr Bull 36(2): 301-13 (2010)
2010  
287
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.
[19900963] Schizophr Bull 36(2): 246-70 (2010)
2009  
288
Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients' nonpsychotic relatives.
[18556667] Schizophr Bull 35(6): 1142-62 (2009)
2009  
289
Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii.
[18552348] Schizophr Bull 35(6): 1163-82 (2009)
2007  
290
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
[17714692] Biochem Pharmacol 74(8): 1192-201 (2007)
2011  
291
Clinical utility of the risperidone formulations in the management of schizophrenia.
[22090797] Neuropsychiatr Dis Treat 7(-): 611-20 (2011)
2011  
292
Pharmacotherapy for treatment-resistant schizophrenia.
[21552316] Neuropsychiatr Dis Treat 7(-): 135-49 (2011)
2011  
293
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.
[21842613] Dialogues Clin Neurosci 13(2): 155-72 (2011)
2010  
294
Executive function, neural circuitry, and genetic mechanisms in schizophrenia.
[19693005] Neuropsychopharmacology 35(1): 258-77 (2010)
2010  
295
Amygdalocortical circuitry in schizophrenia: from circuits to molecules.
[19727065] Neuropsychopharmacology 35(1): 239-57 (2010)
2009  
296
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
[19058862] Trends Pharmacol Sci 30(1): 25-31 (2009)
2010  
297
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
[20963366] Sao Paulo Med J 128(3): 141-66 (2010)
2010  
298
Should we redefine the concept of endophenotype in schizophrenia?
[20658050] Rev Bras Psiquiatr 32(2): 106-7 (2010)
2008  
299
Metabolic comorbidity in schizophrenia.
[18239269] Indian J Med Sci 62(1): 23-31 (2008)
2008  
300
Paliperidone: the evidence of its therapeutic value in schizophrenia.
[21221191] Core Evid 2(4): 261-71 (2008)
2010  
301
Evaluation of the clinical efficacy of asenapine in schizophrenia.
[20642375] Expert Opin Pharmacother 11(12): 2107-15 (2010)
2007  
302
Cholinergic circuits and signaling in the pathophysiology of schizophrenia.
[17349862] Int Rev Neurobiol 78(-): 193-223 (2007)
2010  
303
Neuroimaging of semantic processing in schizophrenia: a parametric priming approach.
[19765623] Int J Psychophysiol 75(2): 100-6 (2010)
2010  
304
Neurocognitive mechanisms of conceptual processing in healthy adults and patients with schizophrenia.
[20004221] Int J Psychophysiol 75(2): 86-99 (2010)
2009  
305
Potential microbial origins of schizophrenia and their treatments.
[19499095] Drugs Today (Barc) 45(4): 305-18 (2009)
2011  
306
2009  
307
Cannabis and psychosis/schizophrenia: human studies.
[19609589] Eur Arch Psychiatry Clin Neurosci 259(7): 413-31 (2009)
2007  
308
Very poor outcome schizophrenia: clinical and neuroimaging aspects.
[17671868] Int Rev Psychiatry 19(4): 345-57 (2007)
2010  
309
Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress.
[20143199] Neurotox Res 18(3-4): 367-76 (2010)
2009  
310
Endophenotypes in schizophrenia: a selective review.
[19223268] Schizophr Res 109(1-3): 24-37 (2009)
2010  
311
Treatment implications of the schizophrenia prodrome.
[21312398] Curr Top Behav Neurosci 4(-): 97-121 (2010)
2007  
312
Workplace violence on workers caring for long-term institutionalized schizophrenic patients in Taiwan.
[17690525] J Occup Health 49(4): 311-6 (2007)
2009  
313
COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia.
[19585392] Pharmacopsychiatry 42(4): 141-4 (2009)
2009  
314
The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia.
[19556835] Stereotact Funct Neurosurg 87(4): 256-65 (2009)
2011  
315
The negative symptoms of schizophrenia: category or continuum?
[21847001] Psychopathology 44(6): 345-53 (2011)
2007  
316
A review of diffusion tensor imaging studies in schizophrenia.
[16023676] J Psychiatr Res 41(1-2): 15-30 (2007)
2010  
317
Studies on the hippocampal formation: From basic development to clinical applications: Studies on schizophrenia.
[19853005] Prog Neurobiol 90(2): 263-75 (2010)
2008  
318
Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia.
[18946539] Front Mol Neurosci 1(-): 6 (2008)
2010  
319
The role of genetics in the etiology of schizophrenia.
[20159339] Psychiatr Clin North Am 33(1): 35-66 (2010)
2003  
320
Molecular genetics of schizophrenia: a critical review.
[14631454] J Psychiatry Neurosci 28(6): 415-29 (2003)
2008  
321
The mediodorsal thalamic nucleus and schizophrenia.
[18982171] J Psychiatry Neurosci 33(6): 489-98 (2008)
2009  
322
Glutamate and dopamine components in schizophrenia.
[19270765] J Psychiatry Neurosci 34(2): 143-9 (2009)
2007  
323
Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?
[17245472] J Psychiatry Neurosci 32(1): 30-52 (2007)
2009  
324
Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?
[19523965] Neuropharmacology 57(3): 193-200 (2009)
2009  
325
What do we know about neuropsychological aspects of schizophrenia?
[19639412] Neuropsychol Rev 19(3): 365-84 (2009)
2007  
326
Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors.
[17545952] CNS Spectr 12(6): 423-7 (2007)
2009  
327
Functional brain networks in schizophrenia: a review.
[19738925] Front Hum Neurosci 3(-): 17 (2009)
2011  
328
GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia.
[21904685] Neural Plast 2011(-): 723184 (2011)
2009  
329
Prepulse inhibition and genetic mouse models of schizophrenia.
[19397931] Behav Brain Res 204(2): 282-94 (2009)
2008  
330
The cognitive neuroscience of memory function and dysfunction in schizophrenia.
[18495087] Biol Psychiatry 64(1): 18-25 (2008)
2010  
331
Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.
[20822517] BMC Psychiatry 10(-): 69 (2010)
2011  
332
A systematic review and meta-analysis of neurological soft signs in relatives of people with schizophrenia.
[21859445] BMC Psychiatry 11(-): 139 (2011)
2010  
333
Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia.
[20846490] BMB Rep 43(9): 593-8 (2010)
2009  
334
From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia.
[19395859] Epigenetics 4(3): 144-9 (2009)
2005  
335
Theories of schizophrenia: a genetic-inflammatory-vascular synthesis.
[15707482] BMC Med Genet 6(-): 7 (2005)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Schizophrenie


  • Search PubMed and many other databases on the combined search terms

    GG: schizophrenia

  • Schizophrenie

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia